(Q46301219)

21 December 2017

title

Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. (English)

1 reference

21 December 2017

1 reference

3

1 reference

21 December 2017

Ab Osterhaus

9

1 reference

21 December 2017

Aude Bonehill

Aude Bonehill

5

0 references

Rob A. Gruters

Rob A Gruters

8

0 references

Kris Thielemans

11

Kris Thielemans

1 reference

21 December 2017

Carlo Heirman

4

Carlo Heirman

1 reference

21 December 2017

Sabine D Allard

1

Sabine D Allard

1 reference

21 December 2017

Joeri L Aerts

12

Joeri L Aerts

1 reference

21 December 2017

Carel A van Baalen

7

Carel A van Baalen

1 reference

21 December 2017

author name string

Katrien Pletinckx

2

1 reference

21 December 2017

Annelies Michiels

6

1 reference

21 December 2017

Patrick Lacor

10

1 reference

21 December 2017

language of work or name

English

0 references

publication date

20 May 2008

1 reference

21 December 2017

published in

Vaccine

1 reference

21 December 2017

volume

26

1 reference

21 December 2017

issue

29-30

1 reference

21 December 2017

page(s)

3735-3741

1 reference

21 December 2017

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Will we be able to 'spot' an effective HIV-1 vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Therapeutic vaccines against HIV need international partnerships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Therapeutic immunization strategies for the control of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Dendritic cells as therapeutic vaccines against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Cancer immunotherapy with mRNA-transfected dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Missense mutations in an infectious human immunodeficiency viral genome: functional mapping of tat and identification of the rev splice acceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.077

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.04.077

1 reference

21 December 2017

1 reference

21 December 2017